Australia · Delayed Price · Currency is AUD Anteris Technologies Global Earnings Call Transcripts
Fiscal Year 2026
-
DurAVR’s development was guided by a disease management approach, resulting in a novel, biomimetic valve with strong anti-calcific properties and superior clinical outcomes. The company targets significant untapped market potential with a proactive launch strategy and aims to justify premium pricing through robust clinical and economic evidence.
-
DurAVR's biomimetic valve platform shows strong clinical performance, including low mean gradients, LV remodeling, and a very low patient-prosthesis mismatch rate. The pivotal PARADIGM trial is set for rapid enrollment, with robust long-term data and high investigator interest.
Fiscal Year 2025
-
The meeting highlighted strong progress in clinical, regulatory, and operational milestones, with a focus on scaling manufacturing and quality to support pivotal trials and commercialization. Board and management updates, robust financial planning, and strategic initiatives position the company as a leader in TAVR innovation.
-
A new biomimetic TAVR valve with superior hemodynamics is entering a $10B market, aiming to combine the ease of balloon expandable delivery with the clinical benefits of self-expanding valves. With pivotal studies starting soon and strong early data, significant growth and investment opportunities are anticipated.
-
Strong initial OJEMDA launch with broad adoption and $57M in early revenue, supported by a robust cash position and ongoing clinical pipeline progress. Steady growth is expected as market penetration deepens, with significant future opportunities in both relapsed/refractory and frontline settings.
Fiscal Year 2024
-
The meeting focused on voting for the Option Scheme, which would cancel existing options and issue equivalent securities in a new Delaware entity, ATGC. The board and independent expert recommended approval, no questions were raised, and voting results were to be announced to the ASX.
-
-
The meeting addressed two resolutions to ratify prior share issues, with poll voting for transparency. No questions were raised by shareholders, and voting results will be released to the ASX. The board reaffirmed its commitment to the company's future.